Home › Companies › JBIO

Jade Biosciences, Inc.

JBIO Rare disease Lead: Phase 1 2 Biotech Distilled articles ↓

Immunology Renal Protein

Most recent annual filing: 2026-03-06

Pipeline (5 active programs)

JADE101

Protein Target: APRIL

IgA Nephropathy Phase 1 subcutaneous Paragon Therapeutics

JADE201

Protein Target: BAFF-R

Rheumatoid Arthritis Preclinical subcutaneous Paragon Therapeutics
Undisclosed indication Preclinical Paragon
Undisclosed indication

JADE301

Undisclosed indication Preclinical Paragon

Biotech Distilled coverage (2)

2026-05-08 UPDATE: Jade Biosciences (JBIO) - The $200M ATM Lands 6 Weeks Before the Monkey-to-Human Verdict 🔒 Paid
2026-05-06 Jade Biosciences (JBIO) - Scientific Deep Dive for JADE101 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.